LUND, Sweden I December 18, 2019 I BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) today announces that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent’s BI-1206, one of its proprietary anti-FcγRllB antibodies and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase l/lla clinical trial for patients with solid tumors.
Martin Welschof, CEO of BioInvent, said, “We are very pleased to have concluded this agreement with Merck, which helps us to expand BI-1206 clinical development to solid tumors in combination with one of the most powerful and successful immune-oncology drugs. This will enable us to build on recent preclinical data which demonstrates BI-1206’s ability to address an important mechanism of resistance to PD-1 inhibition.”
The Phase l/lla clinical trial will evaluate the drug combination in patients with advanced solid tumors, who have been previously treated with anti-PD-1 or anti-PD-L1 antibodies, and is a multicenter, dose-finding, consecutive-cohort, open-label trial. BI-1206 is currently being investigated in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
About BioInvent
BioInvent International AB (publ) (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Three preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company’s validated, proprietary F.I.R.S.TTM technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.
SOURCE: BioInvent
Post Views: 28
LUND, Sweden I December 18, 2019 I BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) today announces that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent’s BI-1206, one of its proprietary anti-FcγRllB antibodies and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase l/lla clinical trial for patients with solid tumors.
Martin Welschof, CEO of BioInvent, said, “We are very pleased to have concluded this agreement with Merck, which helps us to expand BI-1206 clinical development to solid tumors in combination with one of the most powerful and successful immune-oncology drugs. This will enable us to build on recent preclinical data which demonstrates BI-1206’s ability to address an important mechanism of resistance to PD-1 inhibition.”
The Phase l/lla clinical trial will evaluate the drug combination in patients with advanced solid tumors, who have been previously treated with anti-PD-1 or anti-PD-L1 antibodies, and is a multicenter, dose-finding, consecutive-cohort, open-label trial. BI-1206 is currently being investigated in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
About BioInvent
BioInvent International AB (publ) (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Three preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company’s validated, proprietary F.I.R.S.TTM technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.
SOURCE: BioInvent
Post Views: 28
